Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 20:09 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

ClinicalTrials.gov · NCT01185704 · Registry updated: 2014-02-13

Condition / research focus: Polycystic Ovarian Syndrome
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: France
Registry dates and results: Start: 2008-11. Completion: 2012-02 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix acetate (drug) — also listed as: Cetrotide®
Cetrorelix acetate (drug) — also listed as: Cetrotide®
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
Recombinant human follicle stimulating hormone (r-hFSH) (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Research Site
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Sequential Therapy for Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT01403532 · Registry updated: 2014-02-11

Condition / research focus: Hypogonadotropic Hypogonadism; Kallmann Syndrome
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2009-09. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Traditional intervention for HH using HCG and FSH (drug) — also listed as: Tranditional
Sequential intervention for HH using HCG and FSH (drug) — also listed as: Sequential
Sequential intervention for HH using HCG and FSH plus zinc (drug) — also listed as: Sequential plus

Where the study takes place — 1 listed sites

Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

ClinicalTrials.gov · NCT01735422 · Registry updated: 2014-02-04

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Canada
Registry dates and results: Start: 1999-12. Completion: 2001-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hFSH (drug) — also listed as: Gonal-f®
r-hLH (drug) — also listed as: LHadi®
u-hCG (drug)

Where the study takes place — 1 listed sites

Royal University Hospital
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism

ClinicalTrials.gov · NCT02042638 · Registry updated: 2014-01-23

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Gulhane School of Medicine
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2011-01. Completion: 2013-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG 1500 IU three times a week (drug) — also listed as: Pregnyl (Organon) ampule 1500 IU
Pregnyl (hCG) ampule 1500 IU/three times a week (drug)

Where the study takes place — 1 listed sites

Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)

ClinicalTrials.gov · NCT01016210 · Registry updated: 2014-01-17

Condition / research focus: Pregnancy Result Rape
Sponsor: The Baruch Padeh Medical Center, Poriya
Countries with listed sites: Israel
Registry dates and results: Start: 2010-02. Completion: 2013-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuveris (drug)
Leuveris (drug)

Where the study takes place — 1 listed sites

Poriya hospital
Tiberias, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

EXpression PRofile Endometrium Samples Study

ClinicalTrials.gov · NCT01210144 · Registry updated: 2013-12-27

Condition / research focus: In Vitro Fertilization
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: France
Registry dates and results: Start: 2008-08. Completion: 2010-08 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal -f® [r-hFSH] (drug) — also listed as: Gonal-f®, Follitropin Alfa
Ovitrelle® [r-hCG alfa] (drug) — also listed as: Ovitrelle®, Ovidrel®
Gonadotropin-releasing hormone (GnRH) Agonist (drug)
Gonadotropin-releasing hormone (GnRH) Antagonist (drug)

Where the study takes place — 1 listed sites

Research Site
Paris, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome

ClinicalTrials.gov · NCT02022228 · Registry updated: 2013-12-27

Condition / research focus: Infertility and at High Risk of OHSS
Sponsor: Chenshiling
Countries with listed sites: China
Registry dates and results: Start: 2012-07. Completion: 2016-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

triptorelin (drug) — also listed as: triptorelin: Diphereline
hCG (drug)
hCG (drug)

Where the study takes place — 1 listed sites

Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

ClinicalTrials.gov · NCT01071200 · Registry updated: 2013-12-27

Condition / research focus: Reproductive Techniques, Assisted
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Italy
Registry dates and results: Start: 2005-03. Completion: 2009-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) (drug) — also listed as: r-hLH, r-hFSH
r-hFSH (drug)

Where the study takes place — 1 listed sites

Merck Serono S.p.A.
Roma, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT01084265 · Registry updated: 2013-12-27

Condition / research focus: Hypogonadism
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: China
Registry dates and results: Start: 2004-02. Completion: 2005-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human luteinizing hormone (r-hLH) (drug) — also listed as: Luveris (r-hLH)
Recombinant human follicle-stimulating hormone (r-hFSH) (drug) — also listed as: Gonal-F (r-hFSH)
Human chorionic gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Peking Union Medical College Hospital
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH

ClinicalTrials.gov · NCT00417157 · Registry updated: 2013-12-16

Condition / research focus: Infertility; Premature Ovarian Failure
Sponsor: Eugonia
Countries with listed sites: Greece
Registry dates and results: Start: 2007-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant FSH (Puregon, Organon, The Netherlands) (drug)
GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands) (drug)
hCG (Pregnyl, Organon, The Netherlands) (drug)

Where the study takes place — 1 listed sites

Eugonia
Athens, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction

ClinicalTrials.gov · NCT00230815 · Registry updated: 2013-11-28

Condition / research focus: Infertility
Sponsor: EMD Serono
Countries with listed sites: No country reported
Registry dates and results: Start: 2004-07. Completion: 2005-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follitropin alfa injected by Pen device (device) — also listed as: Gonal-f®
Recombinant Human Choriogonadotropin (r-hCG) (device) — also listed as: Ovidrel®, Choriogonadotropin alfa

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

ClinicalTrials.gov · NCT00627406 · Registry updated: 2013-11-27

Condition / research focus: OHSS (Ovarian Hyperstimulation)
Sponsor: Regionshospitalet Viborg, Skive
Countries with listed sites: Denmark
Registry dates and results: Start: 2009-01. Completion: 2011-12 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Buserelin and Pregnyl (drug)
Pregnyl (drug)
Buserelin and Pregnyl (drug)
Pregnyl (drug)

Where the study takes place — 1 listed sites

The Fertility Clinic, Regional Hospital of Skive
Skive, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

ClinicalTrials.gov · NCT01339299 · Registry updated: 2013-11-27

Condition / research focus: Controlled Ovarian Stimulation; Infertility
Sponsor: Regionshospitalet Viborg, Skive
Countries with listed sites: Denmark
Registry dates and results: Start: 2009-10. Completion: 2012-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant luteinizing hormone (r-LH) (drug)
recombinant human chorionic gonadotropin (r-hCG) (drug)

Where the study takes place — 1 listed sites

Fertility Clinic Skive regional Hospital
Skive, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells

ClinicalTrials.gov · NCT01064219 · Registry updated: 2013-11-05

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-02. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotrophin (drug) — also listed as: choriomon

Where the study takes place — 1 listed sites

Cairo University
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Synchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence

ClinicalTrials.gov · NCT01668056 · Registry updated: 2013-09-10

Condition / research focus: Infertility
Sponsor: University of Sao Paulo General Hospital
Countries with listed sites: Brazil
Registry dates and results: Start: 2012-01. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovulation induction with choriogonadotropin alfa (drug)
Aspiration of the dominant follicle (procedure)
Control (other)

Where the study takes place — 1 listed sites

University of Sao Paulo General Hospital
São Paulo, São Paulo, Brazil
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel

ClinicalTrials.gov · NCT01718119 · Registry updated: 2013-08-13

Condition / research focus: Hyperovulation Induction for Assisted Reproduction Treatment
Sponsor: Dong-A Pharmaceutical Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2012-02. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hCG (drug)

Where the study takes place — 3 listed sites

Cha Medical school Boondang-Cha hospital
Seongnam, Gyeong-Gi Do, South Korea
Site recruitment: Not reported
Cha Medical school Gangnam-Cha hospital
Seoul, South Korea
Site recruitment: Not reported
Kwandong university medical school Cheil hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

ClinicalTrials.gov · NCT00328926 · Registry updated: 2013-08-07

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: EMD Serono
Countries with listed sites: United States
Registry dates and results: Start: 2006-03. Completion: 2012-05 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Luveris® 75 IU (drug) — also listed as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Luveris® 25 IU (drug) — also listed as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Placebo (drug)
Recombinant human follicle stimulating hormone (r-hFSH) (drug) — also listed as: Follitropin alfa
Recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Choriogonadotropin alfa

Where the study takes place — 1 listed sites

U.S. Medical Information, 1-888-275-7376
Rockland, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)

ClinicalTrials.gov · NCT01152866 · Registry updated: 2013-08-06

Condition / research focus: Ovulation Induction; Infertility
Sponsor: EMD Serono
Countries with listed sites: No country reported
Registry dates and results: Start: 2003-12. Completion: 2004-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Choriogonadotropin alpha (r-hCG) (drug) — also listed as: Ovidrel

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT01910766 · Registry updated: 2013-07-30

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-01. Completion: 2013-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Coenzyme Q10 (drug) — also listed as: CC 100 mg/day 2-6 and CoQ10,60 mg 3 times day orally on day 2 till hCG
clomiphene citrate (drug)

Where the study takes place — 1 listed sites

Mansoura University Hospitals
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

ClinicalTrials.gov · NCT01888744 · Registry updated: 2013-06-28

Condition / research focus: Reproductive Endocrinology; Fertility; Optimal Stimulation Protocol
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2010-09. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist (drug) — also listed as: Suprefact nasal spray
GnRH antagonist (drug) — also listed as: Orgalutran or Cetrotide
hP-hMG (drug) — also listed as: Menopur
Human chorionic gonadotropin (drug) — also listed as: Pregnyl
Progesterone (drug) — also listed as: Utrogestan vaginal tablets

Where the study takes place — 1 listed sites

Centre for Reproductive Medicine
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 20:09 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

ClinicalTrials.gov · NCT01185704 · Registry updated: 2014-02-13

Condition / research focus: Polycystic Ovarian Syndrome
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: France
Registry dates and results: Start: 2008-11. Completion: 2012-02 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix acetate (drug) — also listed as: Cetrotide®
Cetrorelix acetate (drug) — also listed as: Cetrotide®
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
Recombinant human follicle stimulating hormone (r-hFSH) (drug)

Where the study takes place — 1 listed sites

Research Site
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Sequential Therapy for Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT01403532 · Registry updated: 2014-02-11

Condition / research focus: Hypogonadotropic Hypogonadism; Kallmann Syndrome
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2009-09. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Traditional intervention for HH using HCG and FSH (drug) — also listed as: Tranditional
Sequential intervention for HH using HCG and FSH (drug) — also listed as: Sequential
Sequential intervention for HH using HCG and FSH plus zinc (drug) — also listed as: Sequential plus

Where the study takes place — 1 listed sites

Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

ClinicalTrials.gov · NCT01735422 · Registry updated: 2014-02-04

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Canada
Registry dates and results: Start: 1999-12. Completion: 2001-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hFSH (drug) — also listed as: Gonal-f®
r-hLH (drug) — also listed as: LHadi®
u-hCG (drug)

Where the study takes place — 1 listed sites

Royal University Hospital
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism

ClinicalTrials.gov · NCT02042638 · Registry updated: 2014-01-23

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Gulhane School of Medicine
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2011-01. Completion: 2013-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG 1500 IU three times a week (drug) — also listed as: Pregnyl (Organon) ampule 1500 IU
Pregnyl (hCG) ampule 1500 IU/three times a week (drug)

Where the study takes place — 1 listed sites

Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)

ClinicalTrials.gov · NCT01016210 · Registry updated: 2014-01-17

Condition / research focus: Pregnancy Result Rape
Sponsor: The Baruch Padeh Medical Center, Poriya
Countries with listed sites: Israel
Registry dates and results: Start: 2010-02. Completion: 2013-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuveris (drug)
Leuveris (drug)

Where the study takes place — 1 listed sites

Poriya hospital
Tiberias, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

EXpression PRofile Endometrium Samples Study

ClinicalTrials.gov · NCT01210144 · Registry updated: 2013-12-27

Condition / research focus: In Vitro Fertilization
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: France
Registry dates and results: Start: 2008-08. Completion: 2010-08 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal -f® [r-hFSH] (drug) — also listed as: Gonal-f®, Follitropin Alfa
Ovitrelle® [r-hCG alfa] (drug) — also listed as: Ovitrelle®, Ovidrel®
Gonadotropin-releasing hormone (GnRH) Agonist (drug)
Gonadotropin-releasing hormone (GnRH) Antagonist (drug)

Where the study takes place — 1 listed sites

Research Site
Paris, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome

ClinicalTrials.gov · NCT02022228 · Registry updated: 2013-12-27

Condition / research focus: Infertility and at High Risk of OHSS
Sponsor: Chenshiling
Countries with listed sites: China
Registry dates and results: Start: 2012-07. Completion: 2016-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

triptorelin (drug) — also listed as: triptorelin: Diphereline
hCG (drug)
hCG (drug)

Where the study takes place — 1 listed sites

Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

ClinicalTrials.gov · NCT01071200 · Registry updated: 2013-12-27

Condition / research focus: Reproductive Techniques, Assisted
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Italy
Registry dates and results: Start: 2005-03. Completion: 2009-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) (drug) — also listed as: r-hLH, r-hFSH
r-hFSH (drug)

Where the study takes place — 1 listed sites

Merck Serono S.p.A.
Roma, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT01084265 · Registry updated: 2013-12-27

Condition / research focus: Hypogonadism
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: China
Registry dates and results: Start: 2004-02. Completion: 2005-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human luteinizing hormone (r-hLH) (drug) — also listed as: Luveris (r-hLH)
Recombinant human follicle-stimulating hormone (r-hFSH) (drug) — also listed as: Gonal-F (r-hFSH)
Human chorionic gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Peking Union Medical College Hospital
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH

ClinicalTrials.gov · NCT00417157 · Registry updated: 2013-12-16

Condition / research focus: Infertility; Premature Ovarian Failure
Sponsor: Eugonia
Countries with listed sites: Greece
Registry dates and results: Start: 2007-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant FSH (Puregon, Organon, The Netherlands) (drug)
GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands) (drug)
hCG (Pregnyl, Organon, The Netherlands) (drug)

Where the study takes place — 1 listed sites

Eugonia
Athens, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction

ClinicalTrials.gov · NCT00230815 · Registry updated: 2013-11-28

Condition / research focus: Infertility
Sponsor: EMD Serono
Countries with listed sites: No country reported
Registry dates and results: Start: 2004-07. Completion: 2005-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follitropin alfa injected by Pen device (device) — also listed as: Gonal-f®
Recombinant Human Choriogonadotropin (r-hCG) (device) — also listed as: Ovidrel®, Choriogonadotropin alfa

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

ClinicalTrials.gov · NCT00627406 · Registry updated: 2013-11-27

Condition / research focus: OHSS (Ovarian Hyperstimulation)
Sponsor: Regionshospitalet Viborg, Skive
Countries with listed sites: Denmark
Registry dates and results: Start: 2009-01. Completion: 2011-12 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Buserelin and Pregnyl (drug)
Pregnyl (drug)
Buserelin and Pregnyl (drug)
Pregnyl (drug)

Where the study takes place — 1 listed sites

The Fertility Clinic, Regional Hospital of Skive
Skive, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

ClinicalTrials.gov · NCT01339299 · Registry updated: 2013-11-27

Condition / research focus: Controlled Ovarian Stimulation; Infertility
Sponsor: Regionshospitalet Viborg, Skive
Countries with listed sites: Denmark
Registry dates and results: Start: 2009-10. Completion: 2012-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant luteinizing hormone (r-LH) (drug)
recombinant human chorionic gonadotropin (r-hCG) (drug)

Where the study takes place — 1 listed sites

Fertility Clinic Skive regional Hospital
Skive, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells

ClinicalTrials.gov · NCT01064219 · Registry updated: 2013-11-05

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-02. Completion: 2010-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotrophin (drug) — also listed as: choriomon

Where the study takes place — 1 listed sites

Cairo University
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Synchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence

ClinicalTrials.gov · NCT01668056 · Registry updated: 2013-09-10

Condition / research focus: Infertility
Sponsor: University of Sao Paulo General Hospital
Countries with listed sites: Brazil
Registry dates and results: Start: 2012-01. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovulation induction with choriogonadotropin alfa (drug)
Aspiration of the dominant follicle (procedure)
Control (other)

Where the study takes place — 1 listed sites

University of Sao Paulo General Hospital
São Paulo, São Paulo, Brazil
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel

ClinicalTrials.gov · NCT01718119 · Registry updated: 2013-08-13

Condition / research focus: Hyperovulation Induction for Assisted Reproduction Treatment
Sponsor: Dong-A Pharmaceutical Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2012-02. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hCG (drug)

Where the study takes place — 3 listed sites

Cha Medical school Boondang-Cha hospital
Seongnam, Gyeong-Gi Do, South Korea
Site recruitment: Not reported
Cha Medical school Gangnam-Cha hospital
Seoul, South Korea
Site recruitment: Not reported
Kwandong university medical school Cheil hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

ClinicalTrials.gov · NCT00328926 · Registry updated: 2013-08-07

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: EMD Serono
Countries with listed sites: United States
Registry dates and results: Start: 2006-03. Completion: 2012-05 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Luveris® 75 IU (drug) — also listed as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Luveris® 25 IU (drug) — also listed as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Placebo (drug)
Recombinant human follicle stimulating hormone (r-hFSH) (drug) — also listed as: Follitropin alfa
Recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Choriogonadotropin alfa

Where the study takes place — 1 listed sites

U.S. Medical Information, 1-888-275-7376
Rockland, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)

ClinicalTrials.gov · NCT01152866 · Registry updated: 2013-08-06

Condition / research focus: Ovulation Induction; Infertility
Sponsor: EMD Serono
Countries with listed sites: No country reported
Registry dates and results: Start: 2003-12. Completion: 2004-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Choriogonadotropin alpha (r-hCG) (drug) — also listed as: Ovidrel

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT01910766 · Registry updated: 2013-07-30

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2010-01. Completion: 2013-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Coenzyme Q10 (drug) — also listed as: CC 100 mg/day 2-6 and CoQ10,60 mg 3 times day orally on day 2 till hCG
clomiphene citrate (drug)

Where the study takes place — 1 listed sites

Mansoura University Hospitals
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

ClinicalTrials.gov · NCT01888744 · Registry updated: 2013-06-28

Condition / research focus: Reproductive Endocrinology; Fertility; Optimal Stimulation Protocol
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2010-09. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist (drug) — also listed as: Suprefact nasal spray
GnRH antagonist (drug) — also listed as: Orgalutran or Cetrotide
hP-hMG (drug) — also listed as: Menopur
Human chorionic gonadotropin (drug) — also listed as: Pregnyl
Progesterone (drug) — also listed as: Utrogestan vaginal tablets

Where the study takes place — 1 listed sites

Centre for Reproductive Medicine
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →